AstraZeneca Ends Phase 3 Lung Cancer Drug Trial After Review

Live updates

1. 29d ago

   AstraZeneca Halts Phase 3 Lung Cancer Drug Trial

   AstraZeneca has ended a Phase 3 trial of its lung cancer drug volrustomig, citing low likelihood of success. The trial, known as eVOLVE-Lung02, was testing volrustomig in combination with chemotherapy for metastatic non-small cell lung cancer. The decision to stop the trial was made after a review. AstraZeneca has suffered another setback in its lung cancer pipeline.

   Why it matters

   The trial's failure is a blow to AstraZeneca's lung cancer treatment efforts. Lung cancer is a leading cause of cancer deaths worldwide, and effective treatments are in high demand. The company's decision to halt the trial suggests that the current treatment landscape may not be poised for significant changes with this particular drug.

   What is confirmed

   • AstraZeneca ended a Phase 3 trial of its lung cancer drug volrustomig.
   • The trial, eVOLVE-Lung02, tested volrustomig with chemotherapy for metastatic non-small cell lung cancer.
   • The decision to stop the trial was made after a review.

   What to watch next

   • AstraZeneca's future lung cancer treatment developments
   • Impact on AstraZeneca's lung cancer pipeline
   • Regulatory decisions on volrustomig
   Sources used for this update (5)

   1. WSJ — AstraZeneca Ends Phase 3 Lung Cancer Drug Trial After Review
   2. AstraZeneca — Update on eVOLVE-Lung02 Phase III trial of volrustomig plus chemotherapy in metastatic non-small cell lung cancer
   3. Bloomberg.com — Astra Stops Cancer Drug Trial as Success Seen as Unlikely
   4. Reuters — AstraZeneca suffers another setback as it halts volrustomig lung cancer trial
   5. The Times — AstraZeneca posts two wins and a setback for lung cancer pipeline
   confidence 100%